论文部分内容阅读
报告中国转换酶抑制剂治疗急性心肌梗塞多中心随机双盲安慰剂对照临床试验的一部分，重点探讨卡托普利对前壁与下壁心肌梗塞作用的差异。选择急性心肌梗塞患者１２６３１例，随机分配到卡托普利治疗组或安慰剂对照组，口服卡托普利或安慰剂１２．５ｍｇ３次／ｄ，治疗４周。结果提示：前壁梗塞（ｎ＝６０５７）治疗组４周病死率（９．２％）明显低于对照组（１０．８％），减少死亡危险１５％（Ｐ＝０．０４），但下壁梗塞（ｎ＝３９９０）病死率治疗组（７．２％）与对照组（６．７％）差异无显著性（Ｐ＝０．５４）。发病６ｈ内入选前壁梗塞病死率治疗组（９．５％）显著低于对照组（１３．２％）（Ｐ＝０．００４），但下壁无此差异。非心动过缓（心率≥６０次／分）者总病死率治疗组（９．５％）明显低于对照组（１１．５％；Ｐ＝０．０４），在前壁尤为显著（治疗组８．６％；对照组１２．５％，Ｐ＝０．００１）。结果表明：卡托普利早期治疗前壁心肌梗塞是安全和有益的，但对下壁则无益。
Report the Chinese conversion enzyme inhibitor treatment of acute myocardial infarction randomized double-blind placebo-controlled clinical trial part of the focus on the captopril on the anterior wall and inferior wall myocardial infarction differences. A total of 12631 patients with acute myocardial infarction were enrolled and randomly assigned to either captopril or placebo control, to receive either captopril or placebo 12.5 mg 3 times daily for 4 weeks. The results showed that the 4-week mortality rate (9.2%) in the anterior wall infarction group (n = 6057) was significantly lower than that in the control group (10.8%) and the risk of death was reduced by 15% (P = 0.04) No significant difference was found between the infarct size (n = 3990) CFA-treated group (7.2%) and the control group (6.7%) (P = 0.54). The incidence of anterior wall infarction mortality within 6 hours of onset was significantly lower in the treatment group (9.5%) than in the control group (13.2%) (P = 0.004), but not in the inferior wall. Non-bradycardia (heart rate> = 60 beats / min) with a total mortality of 9.5% was significantly lower in the anterior wall than in the control group (11.5%; P = 0.04) (treatment group 8.6%; control group 12.5%, P = 0.001). The results showed that: captopril early treatment of anterior myocardial infarction is safe and beneficial, but not beneficial to the inferior wall.